An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.

MLA

Ahmed, Fayyaz, et al. “An Open-Label Prospective Study of the Real-Life Use of OnabotulinumtoxinA for the Treatment of Chronic Migraine: The REPOSE Study.” The Journal of Headache and Pain, vol. 20, no. 1, Mar. 2019, p. 26. EBSCOhost, https://doi.org/10.1186/s10194-019-0976-1.

APA

Ahmed, F., Gaul, C., García-Moncó, J. C., Sommer, K., & Martelletti, P. (2019). An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. The Journal of Headache and Pain, 20(1), 26. https://doi.org/10.1186/s10194-019-0976-1

Chicago

Ahmed, Fayyaz, Charly Gaul, Juan Carlos García-Moncó, Katherine Sommer, and Paolo Martelletti. 2019. “An Open-Label Prospective Study of the Real-Life Use of OnabotulinumtoxinA for the Treatment of Chronic Migraine: The REPOSE Study.” The Journal of Headache and Pain 20 (1): 26. doi:10.1186/s10194-019-0976-1.